PF-Atlas › Clinical Trials › NCT03142191
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
CC-90001 · Phase 2
Registry ID
NCT03142191
Phase
Phase 2
Status
Terminated
Drug / intervention
CC-90001
Sponsor
Celgene
Start
2017-07-26
Enrollment
138
Locations
112
About this trial
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03142191 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.